darbepoetin alfa

(redirected from Darbepoetin)
Also found in: Medical.
Translations

darbepoetin alfa

n darbepoetina alfa
References in periodicals archive ?
Darbepoetin alfa is a fastest growing drug class at a CAGR of 12.
The Hyderabad-based firm, which launched pegfilgrastim, rituximab and darbepoetin in India, is reportedly working on trastuzumab and bevacizumab, among others.
A Cleveland Clinic-led study of a drug called darbepoetin alfa showed that the medication did improve red blood cell levels, but didn't improve rates of hospitalization and mortality for anemic heart failure patients, according to the study results published in the New England Journal of Medicine.
Patients received either darbepoetin alfa to a target Hb of 130 g/L or placebo with rescue doses of darbepoetin only if the Hb was less than 90 g/L.
Hyderabad, June 20 -- The Hetero Group, one of the largest manufacturers and suppliers of Active Pharmaceutical Ingredients (APIs) to the Indian pharmaceutical industry, today announced the launch of its first biosimilar product in India, darbepoetin alfa.
The difference in hemoglobin levels between the 1,136 patients assigned to darbepoetin and the 1,142 randomized to the placebo control group became statistically significant after 1 month and remained significant through the study, which had a median follow-up of 28 months, said Dr.
In 2002, most patients were receiving epoetin alfa (65%); however, by 2008, most patients (67%) were receiving darbepoetin alfa (see Table 2).
At that meeting, panelists were is concerned about the higher rate of serious adverse events in patients treated with peginesatide, compared with those treated with darbepoetin, in studies of patients with anemia from CKD who were not on dialysis.
To assist clinicians in determining the risks and benefits of using ESAs in patients with cancer, the American Society of Hematology and the American Society of Clinical Oncology formed a committee to review data and update their guidelines on the use of epoetin and darbepoetin in adults with chemotherapy induced anemia.
The results were an unexpected finding of a study on darbepoetin alpha, which stimulates the production of red blood cells to counteract anemia.
Clinical trials have shown that sc administration of epoetin beta is less painful than sc administration of either epoetin alfa or darbepoetin alfa (Frenken et al.
Amgen manufactures the three ESAs currently marketed in the United States, two epoetin alfa products (Procrit and Epogen) and darbepoetin alfa (Aranesp).